You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNorethindrone
Accession NumberDB00717  (APRD00679)
TypeSmall Molecule
GroupsApproved
Description

A synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(17alpha)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-oneNot AvailableNot Available
17-alpha-Ethynyl-17-hydroxy-4-estren-3-oneNot AvailableNot Available
17-alpha-Ethynyl-19-norandrost-4-en-17-beta-ol-3-oneNot AvailableNot Available
17-alpha-Ethynyl-19-nortestosteroneNot AvailableNot Available
17-alpha-Ethynyl-4-estren-17-ol-3-oneNot AvailableNot Available
17-beta-Hydroxy-19-norpregn-4-en-20-yn-3-oneNot AvailableNot Available
17-Hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-oneNot AvailableNot Available
17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-oneNot AvailableNot Available
17alpha-Ethinyl-19-nortestosteroneNot AvailableNot Available
17alpha-Ethinylestra-4-en-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-17-hydroxy-4-estren-3-oneNot AvailableNot Available
17alpha-Ethynyl-17beta-hydroxy-19-norandrost-4-en-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-nor-4-androsten-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-norandrost-4-en-17beta-ol-3-oneNot AvailableNot Available
17alpha-Ethynyl-19-nortestosteroneNot AvailableNot Available
17alpha-Ethynyl-4-estren-17-ol-3-oneNot AvailableNot Available
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-oneNot AvailableNot Available
17α-ethinyl-19-nortestosteroneNot AvailableNot Available
19-Nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-oneNot AvailableNot Available
19-Nor-17-alpha-ethynylandrosten-17-beta-ol-3-oneNot AvailableNot Available
19-Nor-17-alpha-ethynyltestosteroneNot AvailableNot Available
19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-oneNot AvailableNot Available
19-Nor-17alpha-ethynylandrosten-17beta-ol-3-oneNot AvailableNot Available
19-Nor-17alpha-ethynyltestosteroneNot AvailableNot Available
19-nor-17α-ethynyltestosteroneNot AvailableNot Available
19-Nor-ethindroneNot AvailableNot Available
19-NorethisteroneNot AvailableNot Available
4-Estren-17alpha-ethynyl-17beta-ol-3-oneNot AvailableNot Available
CamilaNot AvailableNot Available
ConludagNot AvailableNot Available
MicronorNot AvailableNot Available
MicronovumNot AvailableNot Available
Mini-PENot AvailableNot Available
Mini-pillNot AvailableNot Available
NorcolutNot AvailableNot Available
NorethindroneNot AvailableNot Available
NorethisteronNot AvailableNot Available
NorethisteroneNot AvailableINN
NorethisteronumLatinINN
NoretisteronaSpanishINN
NoridayNot AvailableNot Available
NorlutenNot AvailableNot Available
NorlutinNot AvailableNot Available
Primolut-NNot AvailableNot Available
UtovlanNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ortho Micronortablet.35 mgoralJanssen Pharmaceuticals, Inc.1973-01-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nor Qdtablet.35 mgoralWatson Pharma, Inc.1973-01-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nora Betablet.35 mgoralWatson Pharma, Inc.2005-05-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Jolivettetablet.35 mgoralActavis Pharma, Inc.2003-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Micronortablet.35 mgoralPhysicians Total Care, Inc.2003-09-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norethindronetablet.35 mgoralMylan Pharmaceuticals Inc.2013-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindronetablet.35 mgoralMylan Pharmaceuticals Inc.2013-07-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindrone Acetatetablet5 mgoralBarr Laboratories Inc.2001-06-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Errintablet.35 mgoralBarr Laboratories Inc.2003-01-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Camilatablet.35 mgoralBarr Laboratories Inc.2002-10-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
NorethindronekitNorthstar Rx LLC2013-09-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
NorethindronekitNorthstar Rx LLC2013-09-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
DeblitanekitNorthstar Rx LLC2014-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
SharobelkitNorthstar Rx LLC2014-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindrone Acetatetablet5 mgoralAv Kare, Inc.2013-06-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Lyzatablet.35 mgoralAfaxys Inc.2013-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindrone Acetatetablet5 mgoralAv Pak2014-11-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aygestintablet5 mgoralTeva Women's Health, Inc.2003-06-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norlyroctablet, film coated.35 mgoralOhm Laboratories Inc.2014-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Camilatablet.35 mgoralPhysicians Total Care, Inc.2003-06-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindrone Acetatetablet5 mgoralAmneal Pharmaceuticals2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindronetablet.35 mgoralLupin Pharmaceuticals, Inc.2011-11-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Jencyclatablet.35 mgoralLupin Pharmaceuticals, Inc.2013-05-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Heathertablet.35 mgoralGlenmark Generics Inc2010-04-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindrone Acetatetablet5 mgoralGlenmark Generics Inc., USA2010-07-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Norethindronetablet.35 mgoralGlenmark Generics Inc.,USA2010-11-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
Primolut-NNot Available
Brand mixtures
Brand NameIngredients
Brevicon 0.5/35 (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 (28 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 0.5/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Brevicon 1/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Brevicon 1/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
CombiPatchNorethindrone + Estradiol
Estalis 140/50 McgEstradiol + Norethindrone Acetate
Estalis 250/50 McgEstradiol + Norethindrone Acetate
Estalis SequiEstradiol + Norethindrone Acetate
EstracombEstradiol + Norethindrone Acetate
femhrtNorethindrone + Ethinyl Estradiol
Femhrt 1/5Ethinyl Estradiol + Norethindrone Acetate
JINTELINorethindrone + Ethinyl Estradiol
Lo Minastrin Norethindrone acetate, ethinyl estradiol, ferrous fumarate
Loestrin 1.5/30 21-day PackEthinyl Estradiol + Norethindrone Acetate
Loestrin 1.5/30 28-day PackEthinyl Estradiol + Norethindrone Acetate
MimveyNorethindrone + Estradiol
Minestrin 1/20 21Ethinyl Estradiol + Norethindrone Acetate
Minestrin 1/20 28Ethinyl Estradiol + Norethindrone Acetate
Norinyl 1/50 - 21-day packMestranol + Norethindrone
Norinyl 1/50 - 28-day packMestranol + Norethindrone
Norinyl 1/50 (21 day)Mestranol + Norethindrone
Norinyl 1/50 (28 day)Mestranol + Norethindrone
Ortho 0.5/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 0.5/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 1/35 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 1/35 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 10/11 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 10/11 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho 7/7/7 Tablets (21 day)Ethinyl Estradiol + Norethindrone
Ortho 7/7/7 Tablets (28 day)Ethinyl Estradiol + Norethindrone
Ortho-Novum 1/50 Tablets (21 day)Mestranol + Norethindrone
Ortho-Novum 1/50 Tablets (28 day)Mestranol + Norethindrone
Select 1/35 (21 day)Ethinyl Estradiol + Norethindrone
Select 1/35 (28 day)Ethinyl Estradiol + Norethindrone
Synphasic (21 day)Ethinyl Estradiol + Norethindrone
Synphasic (28 day)Ethinyl Estradiol + Norethindrone
Salts
Name/CASStructureProperties
Norethindrone Acetate
Thumb
  • InChI Key: IMONTRJLAWHYGT-ZCPXKWAGSA-N
  • Monoisotopic Mass: 340.203844762
  • Average Mass: 340.4559
DBSALT000129
Categories
CAS number68-22-4
WeightAverage: 298.4192
Monoisotopic: 298.193280076
Chemical FormulaC20H26O2
InChI KeyVIKNJXKGJWUCNN-XGXHKTLJSA-N
InChI
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14R,15S)-14-ethynyl-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Ynone
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationNorethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
PharmacodynamicsNorethindrone is a synthetic oral progestin. It is used for contraception or to treat such conditions as secondary amenorrhea, abnormal uterine bleeding, and endometriosis. As an oral contraceptive, norethindrone is available as either a single agent or in combination with an estrogen. Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone.
Mechanism of actionProgestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
AbsorptionNorethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone is rapidly absorbed from norethindrone acetate, in which maximum plasma concentration occur 2 hours post-dose (Tmax). When a single dose is given to healthy women, the Cmax is 26.19 ± 6.19 hours. The AUC (0-inf) is 166.90 ± 56.28 ng/mL*h. Absolute oral bioavailability is approximately 64%. The effect of food on the pharmacokinetics of norethindrone acetate is unknown.
Volume of distribution
  • 4 L/kg
Protein bindingNorethindrone is 36% bound to sex hormone-binding globulin and 61% bound to albumin.
Metabolism

Hepatic. Norethindrone is extensively metabolized, primarily via reduction. It also undergoes sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.

Route of eliminationNorethindrone is excreted in both urine and feces, primarily as metabolites.
Half life8.51 ± 2.19 (when a single dose is given to healthy women)
Clearance
  • 0.4 L/hr/kg [plasma clearance]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9413
Caco-2 permeable+0.8572
P-glycoprotein substrateSubstrate0.6346
P-glycoprotein inhibitor IInhibitor0.5079
P-glycoprotein inhibitor IINon-inhibitor0.9087
Renal organic cation transporterNon-inhibitor0.7603
CYP450 2C9 substrateNon-substrate0.7759
CYP450 2D6 substrateNon-substrate0.9237
CYP450 3A4 substrateSubstrate0.7415
CYP450 1A2 substrateNon-inhibitor0.844
CYP450 2C9 substrateNon-inhibitor0.8688
CYP450 2D6 substrateNon-inhibitor0.9386
CYP450 2C19 substrateInhibitor0.8994
CYP450 3A4 substrateNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7876
Ames testNon AMES toxic0.9319
CarcinogenicityNon-carcinogens0.9417
BiodegradationNot ready biodegradable0.9512
Rat acute toxicity1.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.7744
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
  • Barr laboratories inc
  • Glenmark generics ltd
  • Ortho mcneil janssen pharmaceuticals inc
  • Watson laboratories inc
  • Duramed research inc
  • Glenmark generics ltd india
  • Warner Chilcott
Packagers
Dosage forms
FormRouteStrength
Kit
Tabletoral.35 mg
Tabletoral5 mg
Tablet, film coatedoral.35 mg
Prices
Unit descriptionCostUnit
Ovcon-35 (28) 28 0.4-35 mg-mcg tablet Disp Pack89.09USD disp
Ovcon-50 28 50-1 mcg-mg tablet Disp Pack89.09USD disp
Loestrin 1.5/30 (21) 21 1.5-30 mg-mcg tablet Disp Pack79.32USD disp
Loestrin 1/20 (21) 21 1-20 mg-mcg tablet Disp Pack79.32USD disp
Loestrin Fe 1/20 28 1-20 mg-mcg tablet Disp Pack79.32USD disp
Loestrin Fe 1.5/30 28 1.5-30 mg-mcg tablet Disp Pack77.1USD disp
Loestrin 24 Fe 28 1-20 mg-mcg tablet Disp Pack75.15USD disp
Nor-QD 28 0.35 mg tablet Disp Pack65.87USD disp
Tri-Norinyl (28) 28 0.5/1/0.5-35 mg-mcg tablet Disp Pack62.63USD disp
Ortho-Novum 10/11 (28) 28 35 mcg tablet Disp Pack60.25USD disp
Modicon (28) 28 0.5-35 mg-mcg tablet Disp Pack59.99USD disp
Norinyl 1+35 (28) 28 1-35 mg-mcg tablet Disp Pack55.99USD disp
Ortho-Novum 1/35 (28) 28 1-35 mg-mcg tablet Disp Pack55.99USD disp
Brevicon (28) 28 0.5-35 mg-mcg tablet Disp Pack53.0USD disp
Norinyl 1+50 (28) 28 1-50 mg-mcg tablet 1 Disp Pack = 28 Pills52.99USD disp
Necon 10/11 (28) 28 35 mcg tablet Disp Pack35.99USD disp
Ortho-Novum 7/7/7 (28) 28 0.5/0.75/1-35 mg-mcg tablet Disp Pack33.99USD disp
Necon 0.5/35 (28) 28 0.5-35 mg-mcg tablet Disp Pack32.99USD disp
Necon 1/35 (28) 28 1-35 mg-mcg tablet Disp Pack31.99USD disp
Loestrin fe 1-20 tablet5.23USD tablet
Loestrin 21 1.5-30 tablet3.66USD tablet
Loestrin 21 1-20 tablet3.66USD tablet
Aygestin 5 mg tablet3.27USD tablet
Ovcon-35 28 tablet3.06USD tablet
Loestrin fe 1.5-30 tablet2.75USD tablet
Norethindrone Acetate 5 mg tablet2.75USD tablet
Norethindrone 5 mg tablet2.65USD tablet
Ovcon-50 28 tablet2.62USD tablet
Micronor tablet2.44USD tablet
Nor-q-d tablet2.24USD tablet
Necon 1-35-28 tablet2.11USD tablet
Modicon 28 tablet2.07USD tablet
Tri-norinyl 28 tablet2.01USD tablet
Ortho-novum 1-35-28 tablet1.9USD tablet
Brevicon 28 tablet1.8USD tablet
Norinyl 1+35-28 tablet1.73USD tablet
Norinyl 1+50-28 tablet1.73USD tablet
Demulen 1-50-21 tablet1.67USD tablet
Ortho-novum 7-7-7-21 tablet1.4USD tablet
Errin 0.35 mg tablet1.34USD tablet
Ortho-novum 7/7/7-28 tablet1.33USD tablet
Camila tablet1.32USD tablet
Jolivette tablet1.32USD tablet
Nora-be tablet1.32USD tablet
Norethindrone 0.35 mg tablet1.32USD tablet
Demulen 1-50-28 tablet1.29USD tablet
Ortho micronor tablet1.23USD tablet
Necon 0.5-35-28 tablet1.15USD tablet
Necon 7-7-7-28 tablet1.15USD tablet
Necon 1-50-28 tablet1.05USD tablet
Ortho-novum 7-7-7-28 tablet1.02USD tablet
Micronor (28 Day) 0.35 mg Tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point203.5 °CPhysProp
water solubility7.04 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.97HANSCH,C ET AL. (1995)
logS-4.57ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00668 mg/mLALOGPS
logP2.72ALOGPS
logP3.22ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)17.59ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity87.42 m3·mol-1ChemAxon
Polarizability34.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.3 KB)
SpectraMS1D NMR
References
Synthesis ReferenceNot Available
General Reference
  1. FDA label
External Links
ATC CodesG03AC01G03DC02
AHFS Codes
  • 68:12.00
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (73.9 KB)
Interactions
Drug Interactions
Drug
AbciximabProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
AcenocoumarolProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
AcetohexamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AcitretinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
AlogliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AminoglutethimideMay increase the metabolism of Progestins.
AprepitantMay decrease the serum concentration of Contraceptives (Progestins).
ArtemetherMay decrease the serum concentration of Contraceptives (Progestins).
AtazanavirMay increase the serum concentration of Contraceptives (Progestins).
BoceprevirMay increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone.
BosentanMay decrease the serum concentration of Contraceptives (Progestins).
ButabarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
ButethalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
CanagliflozinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CarbamazepineMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
ChlorpropamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Citric AcidProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
ClobazamMay decrease the serum concentration of Contraceptives (Progestins).
ColesevelamMay decrease the serum concentration of Contraceptives (Progestins).
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DalteparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
DarunavirMay decrease the serum concentration of Norethindrone.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DicoumarolProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Edetic AcidProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
EfavirenzMay decrease the serum concentration of Contraceptives (Progestins).
EnoxaparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Ethyl biscoumacetateProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
ExenatideMay decrease the serum concentration of Oral Contraceptive (Progestins).
FelbamateMay decrease the serum concentration of Contraceptives (Progestins).
Fondaparinux sodiumProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
FosamprenavirContraceptives (Progestins) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Contraceptives (Progestins).
FosaprepitantMay decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect.
FosphenytoinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
GliclazideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlimepirideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GliquidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GlyburideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GriseofulvinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
HeparinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
HeptabarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
HexobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
Insulin AspartHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin DetemirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlargineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin GlulisineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin LisproHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin RegularHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Insulin, isophaneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LamotrigineMay decrease the serum concentration of Contraceptives (Progestins).
LinagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LopinavirMay decrease the serum concentration of Contraceptives (Progestins). Lopinavir may increase the serum concentration of Contraceptives (Progestins).
MetforminHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MethohexitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
MetreleptinMay decrease the serum concentration of Contraceptives (Progestins). Metreleptin may increase the serum concentration of Contraceptives (Progestins).
MifepristoneMay diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins).
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
NelfinavirMay decrease the serum concentration of Contraceptives (Progestins).
NevirapineMay decrease the serum concentration of Contraceptives (Progestins).
OxcarbazepineMay decrease the serum concentration of Contraceptives (Progestins).
PentobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
PerampanelMay decrease the serum concentration of Contraceptives (Progestins).
PhenindioneProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
PhenprocoumonProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
PhenytoinMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
PrimidoneMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
prucaloprideMay decrease the serum concentration of Contraceptives (Progestins).
RepaglinideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
RufinamideMay decrease the serum concentration of Norethindrone.
SaquinavirMay decrease the serum concentration of Contraceptives (Progestins).
SaxagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SecobarbitalMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
SelegilineContraceptives (Progestins) may increase the serum concentration of Selegiline.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SugammadexMay decrease the serum concentration of Contraceptives (Progestins).
SulodexideProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
TelaprevirMay decrease the serum concentration of Contraceptives (Progestins).
ThalidomideContraceptives (Progestins) may enhance the thrombogenic effect of Thalidomide.
TipranavirMay increase the serum concentration of Contraceptives (Progestins).
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolbutamideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TopiramateMay decrease the serum concentration of Contraceptives (Progestins).
Tranexamic AcidContraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.
TreprostinilProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
UlipristalMay diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.
VildagliptinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
VoriconazoleMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
WarfarinProgestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.
Food Interactions
  • Take without regard to meals.

Targets

1. Progesterone receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Progesterone receptor P06401 Details

References:

  1. Mendoza-Rodriguez CA, Camacho-Arroyo I, Garcia GA, Cerbon MA: Variations of progesterone receptor and c-fos gene expression in the rat uterus after treatment with norethisterone and its A-ring reduced metabolites. Contraception. 1999 May;59(5):339-43. Pubmed
  2. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. Pubmed
  3. Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F: Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):21-7. Pubmed
  4. Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91. Pubmed
  5. Pasapera AM, Cerbon MA, Castro I, Gutierrez R, Camacho-Arroyo I, Garcia GA, Perez-Palacios G: Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. Biol Reprod. 1995 Feb;52(2):426-32. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. FDA label

2. Sex hormone-binding globulin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Sex hormone-binding globulin P04278 Details

References:

  1. FDA label

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11